To further accelerate growth, Rarity Bioscience announces today a new strategicinvestment from Belgium based Novalis Biotech. The investment is facilitated
1 mutation in 100 000 wild-types because sensitivity matters
Radically improving cancer diagnostics
Rarity superRCA is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies. The format and flexibility of the technology platform – and read-out based on flow cytometry – makes it suitable for research as well as clinical application.